Literature DB >> 26690770

Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials.

Marko Stojanović1, Milica Prostran1, Miroslav Radenković2.   

Abstract

AIMS: Thiazolidinediones administration is assumed to be related with an improvement of endothelial dysfunction (ED); nevertheless, previous studies have been inconsistent. For this reason, the present meta-analysis was directed to estimate if thiazolidinediones were related to endothelial dysfunction improvement by using flow-mediated dilation (FMD) measurement.
METHODS: Literature search of the PubMed, the Cochrane Library, the Web of Science, and the Scopus databases was performed covering the period until July 01, 2015, for randomized clinical trials that investigated an influence of thiazolidinediones on FMD. For the calculation of the pooled overall effect, a random effect model was used. Meta-regression and subgroup analyses were performed to evaluate the impact of study characteristics on the effect of thiazolidinediones administration on FMD.
RESULTS: This meta-analysis included 16 studies with 812 subjects. The obtained results demonstrated an improvement of endothelial dysfunction measured with FMD (16 studies, 812 subjects; WMD: 2.4 %, 95 % CI = 1.1 to 3.69 %; p = 0.0003). The significant heterogeneity was noted (I (2) = 95 %, p < 0.00001). Subgroup analysis demonstrated that pioglitazone and rosiglitazone were able to improve FMD. Also, thiazolidinediones improved FMD if treatment was longer than 12 weeks and if patients were younger than 65 years. Additionally, a lipid profile was found to influence thiazolidinediones effect on FMD.
CONCLUSION: The results of this meta-analysis demonstrated that thiazolidinediones were able to improve FMD, which in clinical terms can be further translated to the improvement of an impaired endothelial function. Nevertheless, the link between FMD and its predictive clinical relevance still requires further clarification.

Entities:  

Keywords:  Endothelial dysfunction; Flow-mediated dilation; Pioglitazone; Rosiglitazone; Thiazolidinediones

Mesh:

Substances:

Year:  2015        PMID: 26690770     DOI: 10.1007/s00228-015-1999-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  48 in total

1.  Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.

Authors:  Katherine Esposito; Miryam Ciotola; Diego Carleo; Bruno Schisano; Franco Saccomanno; Ferdinando Carlo Sasso; Domenico Cozzolino; Roberta Assaloni; Domenico Merante; Antonio Ceriello; Dario Giugliano
Journal:  Diabetes Care       Date:  2006-05       Impact factor: 19.112

2.  Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.

Authors:  Katerina K Naka; Sophia N Kalantaridou; Maria Kravariti; Aris Bechlioulis; Nikolaos Kazakos; Karim A Calis; Antonis Makrigiannakis; Christos S Katsouras; George P Chrousos; Agathocles Tsatsoulis; Lampros K Michalis
Journal:  Fertil Steril       Date:  2010-08-04       Impact factor: 7.329

3.  Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.

Authors:  Hiroyuki Takase; Ai Nakazawa; Sumiyo Yamashita; Takayuki Toriyama; Koichi Sato; Ryuzo Ueda; Yasuaki Dohi
Journal:  Metabolism       Date:  2007-04       Impact factor: 8.694

4.  Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.

Authors:  Tzung-Dau Wang; Wen-Jone Chen; Wern-Cherng Cheng; Jong-Wei Lin; Ming-Fong Chen; Yuan-Teh Lee
Journal:  Am J Cardiol       Date:  2006-08-28       Impact factor: 2.778

5.  Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.

Authors:  Frank Pistrosch; Kay Herbrig; Beate Kindel; Jens Passauer; Sabine Fischer; Peter Gross
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

6.  Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus.

Authors:  Jean-Paul Albertini; Stephen O McMorn; Hongzi Chen; Richard A Mather; Paul Valensi
Journal:  Atherosclerosis       Date:  2007-02-05       Impact factor: 5.162

7.  Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.

Authors:  G Rudofsky; P Reismann; I A Grafe; I Konrade; Z Djuric; J Tafel; S Buchbinder; M Zorn; P M Humpert; A Hamann; M Morcos; P P Nawroth; A Bierhaus
Journal:  Horm Metab Res       Date:  2007-09       Impact factor: 2.936

8.  Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats.

Authors:  Takayuki Matsumoto; Eri Noguchi; Tsuneo Kobayashi; Katsuo Kamata
Journal:  Free Radic Biol Med       Date:  2007-01-08       Impact factor: 7.376

Review 9.  Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic Implications.

Authors:  Miroslav Radenković
Journal:  Sci Pharm       Date:  2014-08-18

Review 10.  Therapeutic approach in the improvement of endothelial dysfunction: the current state of the art.

Authors:  Miroslav Radenković; Marko Stojanović; Tatjana Potpara; Milica Prostran
Journal:  Biomed Res Int       Date:  2013-01-08       Impact factor: 3.411

View more
  7 in total

Review 1.  Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension.

Authors:  Pasquale Ambrosino; Tiziana Bachetti; Silvestro Ennio D'Anna; Brurya Galloway; Andrea Bianco; Vito D'Agnano; Antimo Papa; Andrea Motta; Fabio Perrotta; Mauro Maniscalco
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-27

Review 2.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

Review 3.  Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.

Authors:  Lorenzo Nesti; Domenico Tricò; Alessandro Mengozzi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-05-18       Impact factor: 9.951

Review 4.  Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease.

Authors:  Nan Wang; Rui Kong; Hui Luo; Xiaorong Xu; Jie Lu
Journal:  PPAR Res       Date:  2017-12-05       Impact factor: 4.964

Review 5.  Role of free fatty acids in endothelial dysfunction.

Authors:  Arijit Ghosh; Lei Gao; Abhimanyu Thakur; Parco M Siu; Christopher W K Lai
Journal:  J Biomed Sci       Date:  2017-07-27       Impact factor: 8.410

6.  Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis.

Authors:  Yuhan Wang; Mingyan Yao; Jincheng Wang; Hongzhou Liu; Xuelian Zhang; Ling Zhao; Xiaodong Hu; Haixia Guan; Zhaohui Lyu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-17       Impact factor: 5.555

7.  The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.

Authors:  Seigo Sugiyama; Hideaki Jinnouchi; Noboru Kurinami; Kunio Hieshima; Akira Yoshida; Katsunori Jinnouchi; Hiroyuki Nishimura; Tomoko Suzuki; Fumio Miyamoto; Keizo Kajiwara; Tomio Jinnouchi
Journal:  Intern Med       Date:  2018-03-30       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.